Trial intelligence / Profile preview

Dasatinib plus chemotherapy for pediatric acute myeloid leukemia with KIT mutation

ChiCTR1900024325Phase 2Recruiting

Sponsor
Children's Hospital of Soochow University
Start
Jul 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of dasatinib in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: Tolerance of dasatinib 80 mg/m2 and Other adverse effects related to dasatinib. Started Jul 2019; status: recruiting.

02

Drugs

dasatinib
03

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on ChiCTR1900024325.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1900024325.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call